Table 3.
Quantitative estimation of valsartan, amlodipine and hydrochlorothiazide in the two formulas of Exforge HCT® Tablets.
| Pharmaceutical dosage form | VAL (D0) |
AML (D0) |
HCT (D0) |
||||
|---|---|---|---|---|---|---|---|
| SS of D0 HCT via AE |
SS of D0HCT via PE |
SS of D0HCT via RE |
CM | AE | PE | RE | |
| Pharmaceutical dosage forma (Exforge HCT®) Formula I (B.N.BKM12) (32.0 VAL: 1.0 AML: 2.5 HCT)* (Found% ± SD) |
100.16 ± 0.57 | 100.66 ± 0.45 | 99.89 ± 0.53 | 99.10 ± 0.64 | 99.20 ± 0.54 | 99.58 ± 0.70 |
99.80 ± 0.42 |
| Pharmaceutical dosage forma (Exforge HCT®) Formula II (B.N.BKN07) (16.0 VAL: 1.0 AML: 2.5 HCT)*(Found% ± SD) |
100.41 ± 0.50 | 100.33 ± 0.37 | 100.08 ± 0.64 | 100.12 ± 0.67 | 100.80 ± 0.55 | 100.93 ± 0.67 | 100.82 ± 0.52 |
a
Average of six experiments.
*
Enriched with 5.0 µg/mL of AML before being analyzed by the proposed methods.